Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

Journal of Neurology, Supplement

Volumn 247, Issue 2, 2000, Pages 36-42

  Chase, Thomas N ^a   Oh, Justin D ^a   Konitsiotis, Spyridon ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

AMPA receptor; Medium spiny neuron; NMDA receptor; Phosphorylation; Signal transduction

Indexed keywords

AMANTADINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; DEXTROMETHORPHAN; DEXTRORPHAN; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SERINE; TYROSINE;

CONFERENCE PAPER; CORPUS STRIATUM; HUMAN; PARKINSON DISEASE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPARKINSON AGENTS; CENTRAL NERVOUS SYSTEM; DYSKINESIAS; HUMANS; PARKINSON DISEASE; RECEPTORS, GLUTAMATE;

EID: 0034102380     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (88)

1. Albin RL, Makowiec RL, Hollingsworth ZR, Dure LS 4th, Penney JB, Young AB (1992) Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 46:35-48
2. Asanuma H, Pavlides C (1997) Neurobiological basis of motor learning in mammals. Neuroreport 8:i-vi
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455
4. Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802
5. Blanchet PJ, Konitsiotis S, Whitmore N, Woodward R, Chase TN (1999) Different effects of subunit specific NMDA antagonists in parkinsonian monkeys. J Pharmacol Exp Ther 290(3):1034-1040
6. Blanchet PJ, Metman LV, Mouradian MM, Chase TN (1996) Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 11: 580-581
7. Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN (1997) Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev 21:447-453
8. Boyce S, Clarke CE, Luquin R, Peggs D, Robertson RG, Mitchell IJ, Sambrook MA, Crossman AR (1990) Induction of chorea and dystonia in parkinsonian primates. Mov Disord 5:3-7
9. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN (1994) Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36: 27-31
10. Cain DP (1997) LTP, NMDA, genes and learning. Curr Opin Neurobiol 7: 235-242
11. Calabresi P, Pisani A, Mercuri NB, Bernardi G (1996) The corticostriatal projection: from synaptic plasticity to basal ganglionic disorders. Trends Neurosci 19:19-24
12. Calabresi P, Saiardi A, Pisani A, Baik JH, Centonze D, Mercuri NB, Bernardi G, Borrelli E (1997) Abnormal synaptic plasticity in the striatum of mice lacking dopumine D2 receptors. J Neurosci 7:4536-4544
13. Carroll CB, Holloway V, Brotchie JM, Mitchell IJ (1995) Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology (Berl) 119:55-65
14. Castro-Alamancos MA, Donoghue JP, Connors BW (1995) Different forms of synaptic plasticity in somatosensory and motor areas of the neocortex. J Neurosci 15:5324-5333
15. Cepeda C, Levine MS (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20:1-18
16. Cervo L, Samanin R (1996) Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res 731: 31-38
17. Chase TN, Oh JD (1999) Striatal mechanisms contributing to the pathogenesis of parkinsonian signs and levodopa-associated motor complications. Ann Neurol (in press)
18. Chase TN (1970) Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. Neurology 20(Suppl):36-40
19. Chen Q, Reiner A (1996) Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res 743:346-352
20. Clarke CE, Sambrook MA, Mitchell IJ, Crossman ARH (1987) Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 78:273-280
21. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Amino-adamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 21:455-468
22. Engber TM, Boldry RC, Chase TN (1991) The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists. Eur J Pharmacol 200: 171-173
23. Engber TM, Boldry RC, Kuo S, Chase TN (1992) Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 581:261-268
24. Engber TM, Papa SM, Boldry RC, Chase TN (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5:2586-2588
25. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552:113-118
26. Ferraro L, Antonelli T, O'Connor WT. Fuxe K, Soubrie P, Tanganelli S (1998) The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J Neurosci 18: 6977-6989
27. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432
28. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427
29. Grace AA, Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4:2866-2876
30. Gaybiel AM, Aosaki T, Flaherty AW, Kimura M (1994) The basal ganglia and adaptive motor control. Science 265:1826-1831
31. Greenamyre JT, O'Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48:977-981
32. Gurd JW (1997) Protein tyrosine phosphorylation: implications for synaptic function. Neurochem Int 31:635-649
33. Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, Houle S (1997) [11C]RTI-32 PET studies of the dopamine transporter in early dopanaive Parkinson's disease: implications for the symptomatic threshold. Neurology 48:1578-1583
34. Henry B, Crossman AR, Brotchie JM (1999) Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155:204-220
35. Herrero MT, Augood SJ, Hirsch EC, Javoy-Agid F, Luquin MR, Agid Y, Obeso JA, Emson PC (1995) Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68:1189-1198
36. Hisatsune C, Umemori H, Inoue T, Michikawa T, Kohda K, Mikoshiba K, Yamamoto T (1997) Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by culmodulin. J Biol Chem 272:20805-20810
37. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51 [Suppl 2]:S2-S9
38. Izquicrdo I, Medina JH (1997) Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 68:285-316
39. Kearney JA, Becker JB, Frey KA, Albin RL (1998) The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience 87:881-891
40. Kita H (1996) Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations. Neuroscience 70: 925-940
41. Klockgether T, Turski L, Honore T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30:717-723
42. Kohr G, Seeburg PH (1996) Subtype-specific regulation of recombinant NMDA receptor-channels by protein tyrosine kinases of the src family. J Physiol (Lond) 492:445-452
43. Konitsiotis S, Blanchet PJ, Lamers E, Verhagen L, Chase TN (1999) The effects of AMPA receptor modulation on parkinsonian symptoms and levodopa-induced dyskinesias in MPTP monkeys. Neurology (in press)
44. Kotter R (1994) Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 44:163-196
45. Le Moine C, Bloch B (1995) D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 inRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 355: 418-426
46. Loschmann PA, Lange KW, Kunow M, Rettig KJ, Jahnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J Neural Transm [P-D Sect] 3:203-213
47. Luquin MR, Obeso JA. Laguna J, Guillen J, Martinez.-Lage JM (1993) The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treuted monkeys, Eur J Pharmacol 235:297-300
48. Marin C, Engber TM, Chaudhuri P, Peppe A, Chase TN (1996) Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors. Psychopharmacology (Berl) 123:215-221
49. Marin C, Papa SM, Engber TM, Bonastre M, Tolosa E, Chase TN (1996) MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205
50. Marin C, Tolosa E, Chase TN (1999) NMDA and Non NMDA antagonist effects on levodopa associated response alterations in parkinsonian rats. Synapse (in press)
51. McEachern JC, Shaw CA (1996) An alternative to the LTP orthodoxy: a plasticity-pathology continuum model. Brain Res Brain Res Rev 22:51-92
52. Melamed E, Hefti F, Wurtman RJ (1980) Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8:558-563
53. Menegoz M, Lau LF, Herve D, Huganir RL, Girault JA (1995) Tyrosine phosphorylution of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 7:125-128
54. Mitchell IJ, Carroll CB (1997) Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci Biobehav Rev 21:469-475
55. Miyawaki E, Lyons K, Pahwa R, Troster AI, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC (1997) Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 20:523-530
56. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bedard PJ, DiPaolo T (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 49:55-62
57. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 (March):314-319
58. Mouradian MM, Heuser IJ, Baronti F. Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 25: 523-526
59. Ng LK, Chase TN, Colburn RW, Kopin IJ (1972) L-dopa in Parkinsonism. A possible mechanism of action. Neurology 22:688-696
60. Nicoll RA, Malenka RC (1995) Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature 377:115-118
61. Oh JD, Del Dotto P, Chase TN (1997) Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett 228:5-8
62. Oh JD, Russell D. Vaughan CL, Chase TN (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and levodopa administration. Brain Res 813:150-159
63. Oh JD, Vaughan CL, Chase TN (1999) Effect of dopamine denervation and dopumine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 813:433-442
64. Ozawa S, Kamiya H, Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54:581-618
65. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18
66. Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578
67. Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69-74
68. Parent A, Asselin MC, Cote PY (1996) Dopaminergic regulation of peptide gene expression in the striatum of normal and parkinsonian monkeys. Adv Neurol 69:73-77
69. Quinn NP (1998) Classification of fluctuations in patients with Parkinson's disease. Neurology 51 [Suppl 2]:S25-S29
70. Sacaan AI, Bymaster FP, Schoepp DD (1992) Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J Neurochem 59:245-251
71. Schultz W (1994) Behavior-related activity of primate dopamine neurons. Rev Neurol (Paris) 150:634-639
72. Seasack SR, Aoki C, Pickel VM (1994) Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 14:88-106
73. Smith AD, Bolam JP (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265
74. Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439-443
75. Suen PC, Wu K, Xu JL, Lin SY, Levine ES, Black IB (1998) NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Brain Res Mol Brain Res 59: 215-228
76. Suzuki T, Okumura-Noji K (1995) NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem Biophys Res Commun 216: 582-588
77. Tan SE, Chen SS (1997) The activation of calcium/calmodulin-dependent protein-kinase II after glutamate or potassium stimulation in hippocampal slices. Brain Res Bull 43:269-273
78. Testa CM, Standaert DG, Young AB, Penney JB Jr (1994) Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 14:3005-3018
79. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, Huganir RL (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 72:5157-5166
80. Ulas J, Cotman C (1996) Dopaminergic denervatiom of striatum results in elevated expression of NR2A subunit. Neuroreport 7:1789-1793
81. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dolto P, Natte R, Chase TN (1998) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 13:414-417
82. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN (1998) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51: 203-206
83. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326
84. Wachtel SR, Abercrombie ED (1994) L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63:108-117
85. Wang JH, Ko GY, Kelly PT (1997) Cellular and molecular bases of memory: synaptic and neuronal plasticity. J Clin Neurophysiol 14:264-293
86. Wang YT, Salter MW (1994) Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature 369: 233-235
87. Wollmuth LP, Kuner T, Seeburg PH, Sakmann B (1996) Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels. J Physiol (Lond) 491:779-797
88. Yu XM, Askalan R, Keil GJ 2nd, Salter MW (1997). NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 275: 674-678